Vanda Pharmaceuticals
VNDA
157 hedge funds and large institutions have $214M invested in Vanda Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 53 increasing their positions, 56 reducing their positions, and 47 closing their positions.
140% more call options, than puts
Call options by funds: $211K | Put options by funds: $88K
5% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 56
2.85% less ownership
Funds ownership: 90.97% → 88.12% (-2.8%)
6% less capital invested
Capital invested by funds: $227M → $214M (-$13.4M)
12% less funds holding
Funds holding: 179 → 157 (-22)
45% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.4M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.07M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.87M |
| 4 |
Morgan Stanley
New York
|
+$1.75M |
| 5 |
Renaissance Technologies
New York
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.89M |
| 2 |
Millennium Management
New York
|
-$4.1M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.06M |
| 4 |
KAM
Krensavage Asset Management
New York
|
-$1.56M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.53M |
VNDA Hedge Fund Activity: Q4 2023 in Review
157 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2023, worth a combined $214M — down 5.9% from $227M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of VNDA and 26 opened new positions — a net loss of 21 holders — while 56 trimmed existing stakes and 53 added.
The largest buyer was BlackRock, adding an estimated $6.4M. The largest seller was Goldman Sachs, cutting an estimated $4.89M.
- 157 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2023, down from 179 in Q3 2023.
- Funds reported $214M of Vanda Pharmaceuticals stock for Q4 2023, down 5.9% quarter-over-quarter.
- 26 funds opened new Vanda Pharmaceuticals positions in Q4 2023 and 47 closed out, a net change of -21 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2023 was BlackRock, an estimated $6.4M added.
- The largest Vanda Pharmaceuticals seller in Q4 2023 was Goldman Sachs, an estimated $4.89M sold.
Based on aggregated 13F filings for Q4 2023.